Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt

Author

Ş. Yaslıkaya

h-index 4 View on Semantic Scholar

We have 3 of 40 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Real-world outcomes of second-line therapy in advanced thymic carcinoma: a multicenter Turkish Oncology Group (TOG) study

Thymic carcinoma (TC) is a rare and aggressive malignancy with limited evidence guiding second-line treatment after prior systemic therapy. We evaluated real-world outcomes of second-line systemic therapy in a multicenter cohort. Adults with unresectable, recurrent, or metastatic TC who received second-lin...

Fatih Kuş, Fatih Atalah, Gökhan Şahin et al. · 0 citations
Open access Oct 2026

Prognostic Significance of CD47 and DHX9 in Metastatic Rectal Cancer

Background/Objectives: The prognosis of metastatic rectal cancer remains poor, and few reliable prognostic biomarkers are available. DHX9 and CD47 have been implicated in colorectal cancer biology, but their prognostic value in metastatic disease remains unclear. We evaluated the associations of DHX9 and CD47 expressio...

Ş. Yaslıkaya, Ş. A. İpek, T. Toyran et al. · 0 citations
Open access Aug 2026

EZH2 Expression and Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Retrospective Cohort Study

These exploratory findings do not support the clinical use of EZH2 as a biomarker at this stage; prospective, multicenter studies using predefined thresholds and standardized immunohistochemical methods are needed to clarify its potential role as a marker complementary to PD-L1.

E. Asarkaya, Hatice Asoğlu, Abdurrahman Aykut et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.